earticle

영어

Stabilization, detoxification, and solubilization of small molecules based therapeutics and natural products can be altered by glycosylation. In vitro glycosylation of small molecules is difficult to scale up as well as costly to implement in industrial level. To overcome these hurdles, Escherichia coli has been engineered by heterologous overexpression of TDP-4-amino-4, 6-dideoxy-D-galactose biosynthetic gene clusters, and glycosyltransferase gene to produce a range of small molecule glycosides. By applying this metabolic engineering approach, flavonoids, the polyphenolic secondary plant metabolites- Quercetin and Kaempferol were glycosylated to produce Quercetin glycoside and Kaempferol glycoside by whole cell biotransformation. This strategy of in vivo glycosylation offers vast combinatorial biosynthesis potential to produce glycosylated natural products by simple fermentation. Key Words: glycosylation, heterologous overexpression, biotransformation, combinatorial biosynthesis potential.